A Single-Arm, Open-Label Phase 4 Study of Nirogacestat in Adult Premenopausal Females With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Latest Information Update: 27 May 2026
At a glance
- Drugs Nirogacestat (Primary)
- Indications Fibroma
- Focus Adverse reactions
- Sponsors SpringWorks Therapeutics
Most Recent Events
- 06 Apr 2026 Planned End Date changed from 30 Mar 2031 to 24 Apr 2031.
- 06 Apr 2026 Planned primary completion date changed from 28 Feb 2031 to 24 Apr 2031.
- 22 Sep 2025 New trial record